SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Collegium Pharmaceutical, Inc. (COLL) trades at a trailing P/E of 17.2, forward P/E of 4.4. Trailing earnings yield is 5.83%, forward earnings yield 22.62%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $20.60.
Criteria proven by this page:
- VALUE (74/100, Pass) — P/E is below market average (17.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+62.7%); earnings yield beats bond yields (5.83%).
- Forward P/E 4.4 (down from trailing 17.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 5.83% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 22.62% as earnings recover.
- Analyst consensus target $58.00 (+62.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 66/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
74/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — COLL
Valuation Multiples
P/E (TTM)17.2
Forward P/E4.4
PEG Ratio0.01
Forward PEG0.01
P/B Ratio3.57
P/S Ratio1.38
EV/EBITDA2.9
Per Share Data
EPS (TTM)$1.98
Forward EPS (Est.)$8.05
Book Value / Share$9.51
Revenue / Share$24.62
FCF / Share$10.33
Yields & Fair Value
Earnings Yield5.83%
Forward Earnings Yield22.62%
Dividend Yield0.00%
Graham Number$20.60
SharesGrow IV$57.61 (+61.6%)
Analyst Target$58.00 (+62.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-4.0 |
-0.04 |
2.80 |
220.79 |
6.50% |
| 2017 |
-7.5 |
0.21 |
5.37 |
19.62 |
- |
| 2018 |
-14.4 |
0.28 |
6.16 |
2.01 |
- |
| 2019 |
-30.3 |
0.38 |
7.87 |
2.32 |
- |
| 2020 |
25.8 |
-0.06 |
3.70 |
2.22 |
- |
| 2021 |
9.1 |
0.06 |
3.22 |
2.36 |
- |
| 2022 |
-31.4 |
0.23 |
4.03 |
1.69 |
- |
| 2023 |
21.6 |
-0.07 |
5.31 |
1.83 |
- |
| 2024 |
13.4 |
0.40 |
4.04 |
1.46 |
- |
| 2025 |
23.3 |
-3.12 |
4.87 |
1.88 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.88 |
$1.71M |
$-94.18M |
-5504.1% |
| 2017 |
$-2.47 |
$28.48M |
$-74.87M |
-262.9% |
| 2018 |
$-1.19 |
$280.41M |
$-39.13M |
-14% |
| 2019 |
$-0.24 |
$296.7M |
$-8.15M |
-2.7% |
| 2020 |
$0.76 |
$310.02M |
$26.75M |
8.6% |
| 2021 |
$1.86 |
$276.87M |
$71.52M |
25.8% |
| 2022 |
$-0.74 |
$463.93M |
$-25M |
-5.4% |
| 2023 |
$1.29 |
$566.77M |
$48.16M |
8.5% |
| 2024 |
$1.86 |
$631.45M |
$69.19M |
11% |
| 2025 |
$1.73 |
$780.57M |
$62.87M |
8.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$8.05 |
$7.70 – $8.28 |
$809.53M |
$806.78M – $812.29M |
3 |
| 2027 |
$7.19 |
$5.27 – $9.31 |
$683.01M |
$636.06M – $729.95M |
3 |
| 2028 |
$7.10 |
$6.42 – $7.87 |
$662.95M |
$614.3M – $718.11M |
1 |
| 2029 |
$8.88 |
$8.03 – $9.84 |
$741.8M |
$687.37M – $803.52M |
1 |
| 2030 |
$9.39 |
$8.49 – $10.40 |
$767.9M |
$711.55M – $831.79M |
1 |
